Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "NS-Pharma"

46 News Found

Briefs: Marksans Pharma and Alkem
News | June 22, 2022

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.


Marskans Pharma acquires Dubai based Access Healthcare
News | April 25, 2022

Marskans Pharma acquires Dubai based Access Healthcare

Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region


SK Biopharmaceuticals joins Pharmaceutical Supply Chain Initiative
Supply Chain | February 25, 2022

SK Biopharmaceuticals joins Pharmaceutical Supply Chain Initiative

PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains


Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore
News | February 11, 2022

Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore

Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021


Marksons Pharma receive final US. FDA approval for Cetirizine Hydrochloride tablets
Drug Approval | January 12, 2022

Marksons Pharma receive final US. FDA approval for Cetirizine Hydrochloride tablets

The product will be marketed under store brand labels and is comparable to the brand Zyrtec


Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
News | November 10, 2021

Marksons Pharma PAT slips to Rs 46.28 in Q2FY22

Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021


Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22
News | August 11, 2021

Marksons Pharma PAT at Rs 62.6 cr. for Q1FY22

The company has tied up with OrbiMed as a financial partner for global reach


Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr
News | July 11, 2021

Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr

The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant


Marksans Pharma Q4 FY21 profit up 86%
News | June 01, 2021

Marksans Pharma Q4 FY21 profit up 86%

The company's operating revenue for Q4 FY21 was Rs. 330.2 crore


Briefs: Zydus, Divi's Laboratories and Relonchem
News | November 17, 2025

Briefs: Zydus, Divi's Laboratories and Relonchem

FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations